AI-Driven Drug Discovery and Development (AID3): Sweden´s Strategic Platform for Pharmaceutical Innovation
| Reference number | |
| Coordinator | Uppsala universitet - Uppsala universitet Inst f farmaci |
| Funding from Vinnova | SEK 1 500 000 |
| Project duration | October 2025 - March 2026 |
| Status | Ongoing |
| Venture | Cluster of Excellence for Cutting-Edge Technologies - calls for proposals |
| Call | Visions for world-leading research and innovation in strategic technology areas |
Important results from the project
The project delivered the planned results and was crucial in bringing together relevant stakeholders and laying the foundation for an excellence cluster with clear societal benefit and industrial relevance in data‑driven drug development. The work focused on designing the cluster structure, including technical platforms and collaboration models. The project also contributed to increased clarity regarding the cluster’s strategic positioning and long‑term success factors.
Expected long term effects
In the long term, the project will strengthen cross‑disciplinary collaboration in drug development. The initiated dialogues between the partners enable a more integrated approach that can shorten the path from discovery to clinical trials, support earlier and better candidate selection, and reduce the risk of late‑stage failures. This will lead to a more sustainable and cost‑effective development process, with AI and automated laboratories playing a central role.
Approach and implementation
A plan for cluster organization, communication, and dissemination was developed. Regular online meetings and continuous dialogue with the project coordinator supported collaboration. Two in‑person meetings addressed cluster structure and partnerships. International collaborations were mapped, including a North American study visit. Collaboration worked well, though revised requirements from Vinnova and the Swedish Research Council affected cluster formation and external engagement.